References:
1. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013; 34(46):3547-56.
2. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011; 123(10):1061-72.
3. Normand C, Linde C, Singh J, Dickstein K. Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines. JACC Hear Fail. 2018; 6(4):308-16.
4. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular Pacing for Atrioventricular Block and Systolic Dysfunction. N Engl J Med. 2013; 368(17):1585-93.
5. Vamos M, Erath JW, Bari Z, Vagany D, Linzbach SP, Burmistrava T, et al. Effects of upgrade versus de novo cardiac resynchronization therapy on clinical response and long-term survival: Results from a multicenter study. Circ Arrhythmia Electrophysiol. 2017; 10(2):e004471.
6. Cheung JW, Ip JE, Markowitz SM, Liu CF, Thomas G, Feldman DN, et al. Trends and outcomes of cardiac resynchronization therapy upgrade procedures: A comparative analysis using a United States National Database 2003–2013. Hear Rhythm. 2017; 14(7):1043-50.
7. St. John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003; 107(15):1985-90.
8. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med. 2009; 361(14):1329-38.
9. Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, et al. The European Cardiac Resynchronization Therapy Survey: Comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure. 2011; 13(9):974-83.
10. Kosztin A, Vamos M, Aradi D, Schwertner WR, Kovacs A, Nagy KV, et al. De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. Heart Failure Reviews. 2018; 23(1):15-26.
11. Beca B, Sapp JL, Gardner MJ, Gray C, AbdelWahab A, MacIntyre C, et al. Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy. CJC Open. 2019; 1(2):93-9.
12. Linde CM, Normand C, Bogale N, Auricchio A, Sterlinski M, Marinskis G, et al. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. Eur J Heart Fail. 2018; 20(10):1457-68.
13. Mady C, Cardoso RHA, Pereira Barretto AC, Da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy. Circulation. 1994; 90(6):3098-102.
14. Oliveira-Filho J, Viana LC, Vieira-De-Melo RM, Faiçal F, Torreão JA, Villar FAGA, et al. Chagas disease is an independent risk factor for stroke: Baseline characteristics of a Chagas disease cohort. Stroke. 2005; 36(9):2015-7.
15. Martinelli Filho M, Peixoto GDL, De Siqueira SF, Martins SAM, Nishioka SAD óri., Pedrosa AAA, et al. A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. Europace. 2018; 20(11):1813-8.
16. Passos LCS, Melo RMV de, Lira YM, Oliveira NFC de, Trindade T, Carvalho W, et al. Chagas disease is associated with a poor outcome at 1-year follow-up after cardiac resynchronization therapy. Rev Assoc Med Bras. 2019; 65(11):1391-6.